These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27563723)

  • 1. Adverse Mucocutaneous Reaction to Pertuzumab in a Patient with HER2-Positive Metastatic Breast Cancer.
    Kowalczyk L; Singer CF; Staudigl C; Weber M; Farr A
    Breast J; 2017 May; 23(3):352-353. PubMed ID: 27563723
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.
    R Ferreira A; Ferreira S; Lambertini M; Maurer C; Martel S; Costa L; Ponde N; de Azambuja E
    Eur J Cancer; 2021 Feb; 144():351-359. PubMed ID: 33388492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertuzumab in HER2-positive early breast cancer: current use and perspectives.
    Eiger D; Pondé NF; de Azambuja E
    Future Oncol; 2019 Jun; 15(16):1823-1843. PubMed ID: 30938542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pertuzumab for the treatment of breast cancer.
    Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
    Expert Rev Anticancer Ther; 2020 Feb; 20(2):85-95. PubMed ID: 30884986
    [No Abstract]   [Full Text] [Related]  

  • 5. Adjuvant pertuzumab improves early breast cancer outcomes.
    Das M
    Lancet Oncol; 2017 Jul; 18(7):e378. PubMed ID: 28625555
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
    Sabatier R; Gonçalves A
    Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
    Hao S; Tian W; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Hu C; Yan J; Luo D
    Oncotarget; 2017 Mar; 8(12):19923-19933. PubMed ID: 28199966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
    De Mattos-Arruda L; Cortes J
    Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PF-05280014: A Trastuzumab Biosimilar.
    Paik J
    BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.
    Drucker AM; Wu S; Dang CT; Lacouture ME
    Breast Cancer Res Treat; 2012 Sep; 135(2):347-54. PubMed ID: 22782294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
    Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in targeting HER2-positive breast cancer.
    Harbeck N
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):55-59. PubMed ID: 29194077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
    Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
    N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2012 Jul; 54(1395):59-60. PubMed ID: 22825690
    [No Abstract]   [Full Text] [Related]  

  • 15. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
    Cortés J; Fumoleau P; Bianchi GV; Petrella TM; Gelmon K; Pivot X; Verma S; Albanell J; Conte P; Lluch A; Salvagni S; Servent V; Gianni L; Scaltriti M; Ross GA; Dixon J; Szado T; Baselga J
    J Clin Oncol; 2012 May; 30(14):1594-600. PubMed ID: 22393084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
    Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the molecule to the clinic--inhibiting HER2 to treat breast cancer.
    Eisenhauer EA
    N Engl J Med; 2001 Mar; 344(11):841-2. PubMed ID: 11248162
    [No Abstract]   [Full Text] [Related]  

  • 18. Pertuzumab (Perjeta) for preoperative use in HER2-positive breast cancer.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):98-9. PubMed ID: 24322664
    [No Abstract]   [Full Text] [Related]  

  • 19. Pertuzumab in HER2-positive breast cancer.
    Sendur MA; Aksoy S; Altundag K
    Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
    Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
    Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.